NAS10029,447+1.73%S&P7,638+1.14%GOLD$4,384−0.08%BTC$76,220+0.09%VIX15.44−12.82%live tape · as of 23:00 UTC · 17 Sep
The Screen · Healthcare · Medical Care Facilities
Chemed Corporation
CHE · the NYSE · USD · Market cap $6.7B · 15,811 employees
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States.
Screened 2026-09-11 · the tape above runs as of 23:00 UTC · 17 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
Chemed Corporation holds its Markdown at $515.97. The statistical read favours the sellers, held for 22 days.
As held on the ledger · 2026-09-11
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 22 days
Price at the screen
$515.97
Valuation
25.98 trailing · 18.75 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.51
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
9.35%
Below 33%
Interest-bearing debt is just 9.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
16.71%
Below 49%
Money owed to the company is 16.7% of assets, under the 49% limit.
Pass
Revenue purity
0.35%
Below 5%
Only 0.3% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-11 screen. The gold marker is the market price at the same screen. A 11.9% margin of safety to the base estimate.
Third-party analyst targets: 4 covering, consensus None. The average target sits +6% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-11 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Hospice care meets zero margin of safety
Every family dealing with terminal illness needs steady support, yet Chemed delivers that service with revenue growth stuck at just 2 percent. The shares sit exactly at our fair value of 510 dollars, giving no cushion at all, and analysts see the stock heading toward 475 dollars. High ROE of 26 percent and a clean ethical pass stand out, but forward earnings at 19 times offer little excitement when growth stays this thin.
The business runs two hospice segments that generate steady cash from essential medical care across the United States. Profit margins hold at 10 percent and the ethical screen clears without issue. Still, unknown competitive protection and single-digit revenue gains leave the investment case balanced at best rather than compelling.
Low growth also caps upside while any reimbursement shift or regulatory pressure could squeeze margins quickly. The current price already prices in the known strengths, leaving little room if execution slips even modestly. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CHE trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-25Accumulation$549.41+7.7%Entry 5
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (4 analysts) rates it buy, with a mean price target of $446.
2026-07-24Accumulation$510.03+21.6%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 21.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (4 analysts) rates it buy, with a mean price target of $446.
2026-07-18Accumulation$419.31+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (4 analysts) rates it buy, with a mean price target of $446.
2026-07-03Accumulation$419.31+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Accumulation$419.31Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
